Jie et al. [73] observed that in HNSCC patients, elevated levels of TIM-3 and PD-1 and in a subset of TILs that were CD8 + , were associated with poor clinical outcomes in those who received cetuximab. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.